Biomarkers

Area of Science:

• Neurology
• Biomarker Discovery
• Medical Diagnostics

Background:

• Alzheimer's disease (AD) diagnosis relies on invasive methods, with blood biomarkers showing promise but lacking standardized detection.
• Inconsistencies in current blood biomarker detection hinder widespread clinical application for AD screening and diagnosis.

Purpose of the Study:

• To conduct a head-to-head comparison of commercially available blood biomarkers for Alzheimer's disease (AD) detection.
• To assess the sensitivity and specificity of plasma biomarkers (Aβ40, Aβ42, t-tau, p-tau) in predicting amyloid pathology confirmed by Aβ-PET.
• To optimize the clinical pathway for AD screening and diagnosis in the Chinese population.

Main Methods:

• The CLEAR-AD study is a cross-sectional study in China involving 400 participants across different cognitive statuses (cognitively normal, MCI, dementia).
• Participants undergo amyloid Positron Emission Tomography (Aβ-PET) scans.
• Plasma biomarkers are measured using various detection methods (e.g., single-molecule immunoassay, digital immunoassay chips) under blinded conditions and compared against Aβ-PET results.

Main Results:

• The study evaluates the diagnostic accuracy of plasma biomarkers against Aβ-PET as the reference standard.
• Receiver operating characteristic (ROC) curves are generated to determine optimal cut-off values for biomarker detection.
• A predictive model integrating multiple biomarkers and clinical data is developed to enhance diagnostic capabilities.

Conclusions:

• The CLEAR-AD study provides essential data on the performance of commercial blood biomarkers for predicting Alzheimer's disease (AD) amyloid pathology.
• Findings will inform the optimization of early AD screening strategies, particularly within the Chinese population.
• The results are expected to guide the development of more effective diagnostic tools for AD.